Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Gluz, Oleg; Nitz, Ulrike; Liedtke, Cornelia; Christgen, Matthias; Grischke, Eva‐Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Bangemann, Nikola; Lindner, Christoph; Küemmel, Sherko; Clemens, Michael; Potenberg, Jochem; Staib, Peter; Kohls, A.; von Schumann, Raquel; Kates, Ronald; Kates, Ronald; Schumacher, Johannes; Wuerstlein, Rachel; Kreipe, Hans; Harbeck, Nadia

doi:10.1093/jnci/djx258

Public

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

Published in JNCI Journal of the National Cancer Institute • Nov 13, 2017

Authors:

Oleg Gluz

Ulrike Nitz

Cornelia Liedtke

Abstract

Background: Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates...

Subject

Gemcitabine

Paclitaxel

Carboplatin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!